Literature DB >> 11276402

New treatments and approaches for attention deficit hyperactivity disorder.

J H Newcorn1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11276402     DOI： 10.1007/s11920-001-0004-3

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


× No keyword cloud information.
  13 in total

1.  Introduction--ADHD comorbidity and treatment outcomes in the MTA.

Authors:  P S Jensen
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

2.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

3.  Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

4.  Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children.

Authors:  B D Garfinkel; P H Wender; L Sloman; I O'Neill
Journal:  J Am Acad Child Psychiatry       Date:  1983-07

5.  Stimulant treatment in young boys with symptoms suggesting childhood mania: a report from a longitudinal study.

Authors:  G A Carlson; J Loney; H Salisbury; J R Kramer; C Arthur
Journal:  J Child Adolesc Psychopharmacol       Date:  2000       Impact factor: 2.576

6.  Symptom profiles in children with ADHD: effects of comorbidity and gender.

Authors:  J H Newcorn; J M Halperin; P S Jensen; H B Abikoff; L E Arnold; D P Cantwell; C K Conners; G R Elliott; J N Epstein; L L Greenhill; L Hechtman; S P Hinshaw; B Hoza; H C Kraemer; W E Pelham; J B Severe; J M Swanson; K C Wells; T Wigal; B Vitiello
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

7.  Multimodal treatment of ADHD in the MTA: an alternative outcome analysis.

Authors:  C K Conners; J N Epstein; J S March; A Angold; K C Wells; J Klaric; J M Swanson; L E Arnold; H B Abikoff; G R Elliott; L L Greenhill; L Hechtman; S P Hinshaw; B Hoza; P S Jensen; H C Kraemer; J H Newcorn; W E Pelham; J B Severe; B Vitiello; T Wigal
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

8.  ADHD comorbidity findings from the MTA study: comparing comorbid subgroups.

Authors:  P S Jensen; S P Hinshaw; H C Kraemer; N Lenora; J H Newcorn; H B Abikoff; J S March; L E Arnold; D P Cantwell; C K Conners; G R Elliott; L L Greenhill; L Hechtman; B Hoza; W E Pelham; J B Severe; J M Swanson; K C Wells; T Wigal; B Vitiello
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

9.  Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment.

Authors:  J M Swanson; H C Kraemer; S P Hinshaw; L E Arnold; C K Conners; H B Abikoff; W Clevenger; M Davies; G R Elliott; L L Greenhill; L Hechtman; B Hoza; P S Jensen; J S March; J H Newcorn; E B Owens; W E Pelham; E Schiller; J B Severe; S Simpson; B Vitiello; K Wells; T Wigal; M Wu
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

10.  Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Authors:  W E Pelham; E M Gnagy; L Burrows-Maclean; A Williams; G A Fabiano; S M Morrisey; A M Chronis; G L Forehand; C A Nguyen; M T Hoffman; T M Lock; K Fielbelkorn; E K Coles; C J Panahon; R L Steiner; D L Meichenbaum; A N Onyango; G D Morse
Journal:  Pediatrics       Date:  2001-06       Impact factor: 7.124
View more
  3 in total

1.  ABHD6 Controls Amphetamine-Stimulated Hyperlocomotion: Involvement of CB1 Receptors.

Authors:  Liting Deng; Katie Viray; Simar Singh; Ben Cravatt; Nephi Stella
Journal:  Cannabis Cannabinoid Res       Date:  2021-10-27

2.  Circuit specific functions of cannabinoid CB1 receptor in the balance of investigatory drive and exploration.

Authors:  Martin Häring; Nadine Kaiser; Krisztina Monory; Beat Lutz
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

3.  Control of exploration, motor coordination and amphetamine sensitization by cannabinoid CB1 receptors expressed in medium spiny neurons.

Authors:  Alipi V Bonm; Izaskun Elezgarai; Christina M Gremel; Katie Viray; Nigel S Bamford; Richard D Palmiter; Pedro Grandes; David M Lovinger; Nephi Stella
Journal:  Eur J Neurosci       Date:  2021-07-13       Impact factor: 3.698
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.